Author:
Cella D,Michaelson M D,Bushmakin A G,Cappelleri J C,Charbonneau C,Kim S T,Li J Z,Motzer R J
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with ‘standard of care’ therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2: 1011–1021
2. Castellano D, García del Muro X, Pérez-Gracia JL, González-Larriba JL, Abrio MV, Ruiz MA, Pardo A, Guzmán C, Cerezo SD, Grande E (2009) Patient reported outcomes in a phase 3, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in European population. Ann Oncol 20: 1803–1812
3. Cella D, Li JZ, Cappelleri JC, Charbonneau C, Kim ST, Chen I, Motzer RJ (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 26: 3763–3769
4. Cella D, Yount S, Brucker PS, Du H, Bukowski R, Vogelzang N, Bro WP (2007) Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 10: 285–293
5. Cella D, Yount S, Du H, Dhanda R, Gondek K, Langefeld K, George J, Bro WP, Kelly C, Bukowski R (2006) Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 4: 191–199
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献